# Yifan Pharmaceutical

> Yifan Pharmaceutical is a VC fund in Hangzhou backing Biotechnology and Biopharma. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Hangzhou, China
- Total investments: 2
- Last investment: Jun 2022
- Lead investor: 50%
- Last updated: Aug 2026
- Website: http://www.yifanyy.com

Yifan Pharmaceutical is a VC fund in Hangzhou focused on Biotechnology and Biopharma. Yifan Pharmaceutical manufactures biochemicals.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 100% |
| Biopharma | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 1 | 50% |
| Singapore | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Generon (Shanghai) Corporation | Generon (Shanghai) Corporation Ltd. is an integrated biotech company developing therapeutic biologics for patients world-wide. Their research & development center is located in Zhang Jiang High-Tech Park, Shanghai, China. their cGMP drug manufacturing facility is located in Economic-Technological Development Area, Beijing, China. Theirmission is “Innovating for Life” to develop innovative therapeutic biologics for global patients with unmet medical needs. They employ their proprietary, cutting-edge technology platforms to discover, develop and manufacture biologic therapeutics. They are focused on “best-in-class” and “first-in-class” recombinant therapeutic proteins to treat cancer, autoimmune and inflammatory diseases. They follow international quality standards for their product development and adhere to regulatory requirements of the CFDA, FDA and EMA. “Innovation and quality” are the soul of Generon in the generation of scientific data and in the processes of drug discovery, development and manufacturing. | $70M | Venture - Series Unknown | Jun 02, 2022 |  |
| Evive Biotech | Evive Biotech develops biological therapies for oncology and inflammatory disorders. The company uses proprietary technology platforms to advance drug candidates. It also manages drug development, regulatory compliance, and commercial-scale manufacturing for biologics. | $70M | Venture - Series Unknown | Jun 02, 2022 |  |

2 of 2 investments shown.

## Co-investors
- [Sino Biopharmaceutical](https://shizune.co/investors/profile/sino-biopharmaceutical) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Bossa Invest](https://shizune.co/investors/profile/bossanova-investimentos) — VC Fund
- [Almi Invest](https://shizune.co/investors/profile/almi-invest) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund

## FAQ

### What does Yifan Pharmaceutical invest in?

Yifan Pharmaceutical invests primarily in Biotechnology and Biopharma startups, most often at Venture - Series Unknown stage. Most of the 2 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Yifan Pharmaceutical last invest?

The most recent investment recorded for Yifan Pharmaceutical closed in Jun 2022. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co